Virtual Medical Academy

Overview

The event is to present the relevant unmet needs existing in the dermatology field regarding psoriasis and Atopic dermatitis the suffering on the patients that have actually this disease. The event will have local dermatology leaders who will present the content in a very high level of scientific manner. Specifically, the event will consist of having a very good comprehensive review to understand what the mechanism of action of JAK inhibitors & IL-17 are and what are the implications on patients and on the everyday clinical practice of the members among the different situations that they can look at.
Moreover, the event consists of resuming a very good comprehensive review to understand the results obtained on the important Baricitinib’s clinical trials & Ixikizumab . In addition, the speaker will discuss in deep manner one of such phase iii clinical trials that really express the efficacy and safety results when compared to current standard of care, including data on patient reported outcomes which will help as well discuss the need to enhance the relevance of such results. This is a very interesting part of the event as all the assistants will be able to understand the value of a new molecules and its applicability to their most difficult challenges they might face with their patients with PsO & AD. The next steps are to have a deep discussion on the clinical practice of the use of Baricitinib in order to elaborate the most valuable discussions that could benefit every single rheumatologist if they would obtain any doubt regarding the existing unmet needs on the treatment for rheumatoid arthritis, and as well, if by any means, they would have doubt about the use of this new molecule with this new mechanism of action.
We will present a comprehensive review of additional benefits of Baricitinib that not only includes the oral administration and the once a day pill, but also good review of what dose tapering option of Baricitinib means to the clinical practice of dermatologist, and validate such tapering options with the clinical results in different sub-analysis. Last, a comprehensive review of safety data will be shared to present the most relevant information that any dermatologist would need to have to understand the risk benefit profile of Baricitinib